To study the contents of CXC motif chemokine ligand 10 (CXCL10) and angiopoietin-1 (Ang-1) in acute myelogenous leukemia(AML) and clarify their clinical significance.

The serum samples from 20 volunteers (control group), 41 AML patients (observation group) were collected, and ELISA was used to detect the contents of CXCL10 and Ang-1.

The contents of CXCL10 and Ang-1 in control group were (1.569±0.485) ng/ml and (0.839±0.334) ng/ml, which were (2.780±0.627) ng/ml and (1.456±0.398) ng/ml in observation group before treatment, there were significant differences (t=7.582, 5.974, P<0.05). The contents of CXCL10 and Ang-1 in observation group after treatment were (1.693±0.579) ng/ml and (1.001±0.373) ng/ml, which were reduced than those before treatment (t=16.470, 10.474, P<0.05). The contents of CXCL10 and Ang-1 in complete remission patients in observation group were (1.409±0.463) ng/ml and (0.868±0.271) ng/ml, there was no significant difference compared with control group (q=1.667, 0.414, P>0.05). The levels of CXCL10 and Ang-1 in non-complete remission patients in observation group were (2.185±0.409) ng/ml and (1.230±0.422) ng/ml, which were markedly higher than those in control group (q=5.549, 4.887, P<0.05) and complete remission patients in observation group (q=7.390, 4.738, P<0.05). There was positive correlation of serum contents of CXCL10 and Ang-1 with serum contents of AML(r=0.438, P<0.05).

Different contents of serum CXCL10 and Ang-1 are found in different disease states in AML patients, and CXCL10 is positively correlated with Ang-1, which may be related to the pathogenesis and prognosis of AML.

Acute myelogenous leukemia; CXC chemo-kine ligand-10; Angiopoietin-1